Gold prices fall as geopolitical tensions ease; U.S. CPI looms
Director Mark Foletta of Dexcom INC (NASDAQ:DXCM) sold 2,750 shares of common stock on July 15, 2025, according to a recent SEC Filing. The sales were executed in two transactions, with prices ranging from $85.1672 to $86.03, resulting in a total value of $234,216. The company, currently valued at $33 billion, trades at a P/E ratio of 62.3 and maintains a "GREAT" financial health score according to InvestingPro.
The first sale involved 2,742 shares at a weighted average price of $85.1672, executed in multiple trades ranging from $84.815 to $85.44. The second sale involved 8 shares at $86.03.
These shares were sold by The Foletta Family Trust DTD 1/30/2015, for which Foletta serves as trustee, under a pre-arranged 10b5-1 trading plan adopted on March 13, 2025. Following the transactions, the Trust continues to hold 53,871 shares. Foletta also directly owns 5,731 shares of unvested restricted stock units which were granted on May 8, 2025 and shall vest on the earlier of the one year anniversary of the grant date or the date of DexCom , Inc.’s 2026 Annual Meeting of Stockholders.
In other recent news, Dexcom, Inc. has initiated a recall of certain glucose monitoring receivers due to a speaker malfunction that may prevent alerts for dangerous blood sugar levels. This issue affects the Dexcom G6, G7, ONE, and ONE+ receivers, with the FDA classifying it as the most serious type of recall. The malfunction has resulted in at least 56 reported injuries, although no fatalities have been reported. Meanwhile, Truist Securities has initiated coverage on Dexcom with a Buy rating, citing the company’s potential in the continuous glucose monitoring market. Piper Sandler also maintained its Overweight rating on Dexcom, highlighting the company’s expected market share gains among basal insulin patients. Goldman Sachs has started covering Dexcom with a Buy rating and a $104 price target, noting the untapped potential in consumer adoption. RBC Capital Markets reiterated an Outperform rating and a $100 price target, emphasizing Dexcom’s potential to exceed its financial targets by 2025. These developments reflect a mix of challenges and opportunities for Dexcom, as it navigates product recalls and anticipates growth in the diabetes monitoring market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.